Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 14, 2022
Reporting Period: Event date November 14, 2022; Report signed November 18, 2022.
Context: The Company entered into a material definitive agreement to conduct a private placement offering of equity securities.
Key Financial Metrics
This filing reports on a capital raise event rather than periodic operating results. Specific metrics include:
- Gross Proceeds: Approximately $18.9 million.
- Net Proceeds: Approximately $17.9 million (after deducting placement agent commissions, expenses, and estimated offering expenses).
- Placement Agent Commission: 5% of gross proceeds paid to Lake Street Capital Markets, LLC.
- Units Sold: 4,093,141 units.
- Offering Price: $4.625 per Unit.
- Unit Composition: Each Unit consists of two shares of Common Stock and one Warrant to purchase one share of Common Stock.
- Warrant Exercise Price: $4.50 per share.
Note: The filing text does not provide clear values for revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the execution of a private placement offering on November 14, 2022. This transaction results in:
- Issuance of 8,186,282 shares of Common Stock (2 shares per unit).
- Issuance of 4,093,141 Warrants.
- Immediate increase in liquidity via net proceeds of approximately $17.9 million.
- Entry into a Registration Rights Agreement requiring the filing of a registration statement within 60 days of the final closing date.
Guidance, Outlook, and Risks
Management Commentary: The Company utilized the proceeds to fund operations and growth, though specific strategic allocation details are not elaborated in this summary text.
Warrant Terms and Risks:
- Exercise Period: Warrants are exercisable beginning six months after the initial closing date and expire seven years after the initial closing date.
- Beneficial Ownership Limitation: Warrants cannot be exercised if the holder would beneficially own more than 19.99% of outstanding Common Stock.
- Call Provision: The Company may call for cancellation of Warrants if the volume-weighted average price exceeds 300% of the exercise price for 30 consecutive trading days, provided average daily trading volume exceeds $500,000 and other conditions are met.
Contingencies: The sale of securities was made in reliance on Section 4(a)(2) of the Securities Act and Regulation D. The Company is obligated to maintain the effectiveness of the Registration Statement until the Registrable Securities are sold or eligible for sale under Rule 144.
Investor Verification Checklist
- Verify the final closing date of the Offering to determine the exact start of the 60-day registration filing window.
- Confirm the total number of shares outstanding post-closing to assess dilution impact.
- Review the full text of the Subscription Agreement (Exhibit 10.1) for specific covenants and conditions.
- Monitor the Company's ability to file the required Registration Statement within the mandated 60-day period.
- Check subsequent filings for the actual use of the $17.9 million in net proceeds.